At what enterprise value was QUIPMENT acquired in 2026?

You can find the full valuation details of QUIPMENT on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of QUIPMENT when it was acquired by SAGARD?

The exact EV/EBITDA multiple for QUIPMENT is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was QUIPMENT acquired by SAGARD?

QUIPMENT was acquired by SAGARD in 2026.

What was the revenue of QUIPMENT at the time of the deal?

The revenue of QUIPMENT at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the QUIPMENT acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the QUIPMENT deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/capital-developpement/quipment-accueille-sagard-newgen-2210546

← DATABASE

Home Database Healthcare & PharmaQUIPMENT

01/2026

QUIPMENT acquired by SAGARD

FRANCE Healthcare Services REV 25M - 50M EUR

Context

Sagard NewGen acquired a significant minority stake in Quipment, fifteen years after its inception. The deal aims to accelerate Quipment's international expansion, particularly in the US and Asia, and to support its digital transformation. This transaction follows a similar move in the sector by Antin IP with Emsere.

QUIPMENT, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Quipment is a leading international specialist in the management and provision of medical equipment and clinical trial supplies for the global pharmaceutical and biotechnology industries. Headquartered in France, the company provides a comprehensive "Equipment-as-a-Service" model that covers the entire lifecycle of clinical trial logistics, including sourcing, global distribution, maintenance, calibration, and decommissioning of medical devices. Its business model is designed to de-risk complex multicenter clinical trials by ensuring that investigators have standardized, compliant, and ready-to-use equipment across diverse geographical sites. The organization leverages a robust digital platform for real-time asset tracking and regulatory documentation, which is critical for maintaining data integrity and trial timelines.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2026	RADNET	GLEAMER	FRANCE	Health Tech
03/2026	THERMO FISHER SCIENTIFIC	CLARIO HOLDINGS	UNITED STATES	CRO / Clinical Trials
01/2026	TPG	OPTUM UK	UNITED KINGDOM	Health Tech
01/2026	PERMIRA	CARNE GROUP	IRELAND	Healthcare Services
01/2026	ANTIN INFRASTRUCTURE	EMSERE	NETHERLANDS	CRO / Clinical Trials
12/2025	PHARMA EQUITY GROUP	OTIOM	DENMARK	Health Tech
11/2025	EURAZEO	EXCELYA	FRANCE	CRO / Clinical Trials
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Hospital Logistics
10/2025	EVOLEM	APPERTON	FRANCE	Sterilization & Hygiene
05/2025	FIVE ARROWS	HUBLO	FRANCE	Health Tech

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of QUIPMENT by SAGARD are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: quipment

Acquirer: sagard